Inclusion Criteria:  Children and adolescents, aged 2-18 years, with moderate-to-severe atopic dermatitis (diagnosed according to the UK working party criteria) Patient and parents/guardians able to participate in the study and willing to give written informed consent EASI (Eczema Area Severity Index) ≥ 6 at screening and baseline (corresponding with moderate-to-severe disease) IGA (Investigator Global Assessment) ≥ 3 at screening and baseline (corresponding with moderate-to-severe disease)  Exclusion Criteria:  Children under the age of 2 years and patients older than 18 years Contraindication for ciclosporin Contraindication for dupilumab Patient (or one of the parents/guardians) not willing to be randomized Children with a history of any known primary immunodeficiency disorder Children with a history of cancer EASI < 6 at screening or baseline IGA < 3 at screening or baseline